Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × mirdametinib × CNS × Clear all

Phase

Status

Recruiting 2 Completed 1 Available 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2 Thoracic 1 Other solid neoplasm 1 CNS 1 Breast 1

Conditions

Neurofibromatosis 1 1 Neurofibroma 1

Interventions

Temozolomide 267 Radiotherapy 198 Bevacizumab 126 Carboplatin 78 Cyclophosphamide 74 Etoposide 70 Irinotecan 62 Vincristine 58 Magnetic Resonance Spectroscopy 58 Filgrastim 57 Radiation 53 Cisplatin 48 Radiosurgery 47 Surgical Procedures, Operative 34 Lomustine 34 Peripheral Blood Stem Cell Transplantation 33 Carmustine 33 Topotecan 32 sargramostim 31 Granulocyte Colony-Stimulating Factor 31 Melphalan 28 Doxorubicin 28 Chemotherapy, Adjuvant 28 Nivolumab 27 Radiotherapy, Intensity-Modulated 26 Isotretinoin 26 Everolimus 25 Erlotinib Hydrochloride 25 Vorinostat 22 Thiotepa 20

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02096471 2019-01-10

MEK Inhibitor

University of Alabama at Birmingham

Phase 2 Completed

19 enrolled 14 charts

Neurofibroma, Neurofibromatosis 1

Data powered by HemOnc (CC BY 4.0) Colophon ⚡